[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362253-105":59,"doc-detail-362253-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-the-ubiquitinproteasome-system-and-drug-therapy-in-colorectal-cancer","Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer","","Colorectal cancer (CRC) remains a major global health threat, with limited effectiveness of surgery, chemotherapy, and radiotherapy for advanced or recurrent disease. This review focuses on the ubiquitin–proteasome system (UPS) as a central regulator of protein homeostasis that shapes CRC initiation, progression, tumor immunity, and chemotherapy resistance. It summarizes small-molecule UPS modulators and emerging approaches such as PROTAC and molecular glue technologies, emphasizing mechanisms, therapeutic opportunities, and clinical translation prospects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-ubiquitinproteasome-system-and-drug-therapy-in-colorectal-cancer/362253/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-ubiquitinproteasome-system-and-drug-therapy-in-colorectal-cancer/362253.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is the ubiquitin–proteasome system (UPS) considered a therapeutic target in colorectal cancer?","Question",{"text":112,"@type":113},"The UPS regulates cellular protein homeostasis and influences signaling pathways, tumor immunity, and resistance to chemotherapy, which are key processes in colorectal cancer progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do small molecules targeting the UPS work in colorectal cancer treatment?",{"text":117,"@type":113},"They intervene in critical UPS steps, such as E1, E2, and E3 enzyme activity, or directly target the proteasome to modulate degradation of oncogenic proteins and hinder tumor progression.",{"name":119,"@type":110,"acceptedAnswer":120},"What new strategies are discussed beyond traditional UPS inhibitors?",{"text":121,"@type":113},"The review highlights PROTAC and molecular glue technologies, which can selectively degrade specific oncogenic proteins and expand therapeutic options for colorectal cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362253,1790654321,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Journal of Molecular Cell Biology (2025), 17(6), mjaf027 [https://doi.org/10.1093/jmcb/mjaf027](https://doi.org/10.1093/jmcb/mjaf027)  \nPublished online August 22, 2025  \nReview  \nTargeting the ubiquitin–proteasome system and drug therapy in colorectal cancer  \nRuixin Su1 ,†, Yingying Shao2 ,3 ,†, Qian Wang1 , Donghui Liu1 , Yitong Wang1 , Dexin Kong1 , * , and Yuling Qiu1 , *  \n1 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China  \n2 School of Medicine, Nankai University, Tianjin 300071, China  \n3 National Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China † These authors contributed equally to this work.  \n* Correspondence to: Dexin Kong, E-mail: [kongdexin@tmu.edu.cn](kongdexin@tmu.edu.cn); Yuling Qiu, E-mail: [qiuyuling@tmu.edu.cn](qiuyuling@tmu.edu.cn)  \nEdited by Weiwei Yang  \nColorectal cancer (CRC) is the third most prevalent malignancy worldwide and the second leading cause of cancer-associated deaths, posing a signiﬁcant threat to human health. Given the limited therapeutic options and poor prognosis associated with CRC, thereis an urgent need to develop new targeted therapeutic strategies to enhance clinical outcomes. The ubiquitin–proteasome system (UPS), a central regulator for cellular protein homeostasis, plays a pivotal role in the initiation and progression of CRC. The UPS modulates several essential signaling pathways and is involved in regulating tumor immunity and resistance to chemotherapy. Thus, the UPS contributes signiﬁcantly to the complex biological processes underlying CRC pathogenesis. In recent years, smallmolecule compounds targeting the UPS have exhibited considerable therapeutic potential in CRC treatment. These drugs intervene in crucial steps in the UPS, such as the activity of E1, E2, and E3 enzymes, or directly target the proteasome, thereby regulating the degradation of oncogenic proteins and eﬀectively impeding tumor progression. Moreover, emerging therapeutic strategies such as proteolysis-targeting chimera (PROTAC) and molecular glue technologies selectively degrade speciﬁc oncogenic proteins, thereby oﬀering new avenues and promising opportunities for CRC treatment.  \nKeywords: colorectal cancer (CRC), ubiquitin–proteasome system (UPS), drug therapy, proteolysis-targeting chimera (PROTAC), molecular glue  \nIntroduction  \nColorectal cancer (CRC) ranks as the third most common malignancy worldwide and is characterized by persistently high incidence and mortality rates, representing a signiﬁcant global health threat. Although conventional treatments such as surgery, chemotherapy, and radiotherapy have shown some clinical beneﬁt, outcomes for patients with advanced or recurrent CRC remain largely unsatisfactory. This underscores an urgent  \nReceived November 10, 2024 . Revised May 19, 2025 . Accepted August 18, 2025 .© The Author(s) (2025) . Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, CEMCS, CAS.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([https://creativecommons.org/licenses/by](https://creativecommons.org/licenses/by)nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please  \ncontact [journals.permissions@oup.com](journals.permissions@oup.com)  \nneed for novel therapeutic strategies to enhance patient prognosis and overall survival. Recent studies have identiﬁed the ubiquitin–proteasome system (UPS) as a promising therapeutic ","cbCaibApdCWY5kl3","https://ap.wps.com/l/cbCaibApdCWY5kl3","pdf",1004609,12,"English","# Introduction\n## Protein degradation pathways\n## UPS-targeted therapies in colorectal cancer\n## PROTAC and molecular glue technologies\n## Advantages, limitations, and future prospects","[{\"question\":\"Why is the ubiquitin–proteasome system (UPS) considered a therapeutic target in colorectal cancer?\",\"answer\":\"The UPS regulates cellular protein homeostasis and influences signaling pathways, tumor immunity, and resistance to chemotherapy, which are key processes in colorectal cancer progression.\"},{\"question\":\"How do small molecules targeting the UPS work in colorectal cancer treatment?\",\"answer\":\"They intervene in critical UPS steps, such as E1, E2, and E3 enzyme activity, or directly target the proteasome to modulate degradation of oncogenic proteins and hinder tumor progression.\"},{\"question\":\"What new strategies are discussed beyond traditional UPS inhibitors?\",\"answer\":\"The review highlights PROTAC and molecular glue technologies, which can selectively degrade specific oncogenic proteins and expand therapeutic options for colorectal cancer.\"}]","Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer | PDF",1790146904,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e068fdb8dae147328716c6306bf65e.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e214ea6161b8ede1e093d15b992d9a19.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b9fa34cfbda0431afee2dab8a134a2b.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/708f1f032a82a55862f2e8edae421b64.webp",980,1265]